Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in ...

On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and ...

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...

In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms ...

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption ...

Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions ...

Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Early adopters of biosimilars have paved the way for broader acceptance by sharing real-world success strategies, overcoming initial resistance, and highlighting best practices for integration and ...

The biosimilar ocrelizumab candidate (Xacrel) was found to be equivalent to the originator product (Ocrevus) in reducing the annualized relapse rate and showed comparable safety and efficacy over 96 ...